Charles Olson, MD
Interventional Cardiology · Omaha, NENPI 1699736553
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,949 of the $11,619 with a category attached, or 77.0%. 36 manufacturers reported payments, led by Edwards Lifesciences at 33.5% of the total. Reporting peaked in 2023 at $3,299 and has fallen 69.9% since, to $992 in 2025.
Across 375 payments — averaging $30.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Medtronic$2K
- Abbott$2K
- Boston Scientific$820
- Novartis$472
- Abiomed$458
- plus $1K from 30 others
Across 66 payments — averaging $1580.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$78K
- Bayer$13K
- Janssen Research & Development, LLC$10K
- Amgen$3K
- Novo Nordisk AS$1K
What the payments were for
- Travel & lodging$2,67023%
- Food & beverage$8,94977%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 120 | $3,896 |
| Medtronic(2 entities) | 79 | $2,256 |
| Abbott | 38 | $2,224 |
| Boston Scientific | 27 | $820 |
| Novartis | 25 | $472 |
| Abiomed | 6 | $458 |
| Sanofi-aventis U.S. LLC | 11 | $167 |
| Philips North America LLC | 3 | $159 |
| Amgen | 9 | $128 |
| AstraZeneca | 3 | $111 |
| Amarin Pharma, Inc. | 7 | $108 |
| Boehringer Ingelheim | 6 | $91 |
| Bridgebio Pharma, Inc. | 2 | $66 |
| Cardiva Medical, Inc. | 2 | $59 |
| Scpharmaceuticals Inc. | 3 | $57 |
| Gilead | 4 | $52 |
| Shockwave Medical, Inc | 1 | $44 |
| Merck | 3 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Johnson & Johnson | 3 | $38 |
| Terumo Medical Corporation | 2 | $27 |
| Sanofi | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Pfizer | 2 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Zimmer Biomet | 1 | $20 |
| Atricure, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Opsens Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Penumbra, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$2,032
- Mitra Clip system$815
- CoreValve Evolut$414
- Impella$270
- COREVALVE EVOLUT R$243
- Quadra Assura CRT Defibrillator$157
- SAPIEN 3 Ultra RESILIA$144
- Xience Sierra Coronary Stent System$142
- AVEIR$139
- GENERAL - STRUCTURAL HEART$122
- CROSSBOSS$116
- Confirm Rx$115
- Edwards SAPIEN 3 Transcatheter Heart Valve$106
- Watchman$103
- LEQVIO$103
How this compares
$11,619 in reported general payments places this provider in the 65th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 425 | $449,407 |
| EntrestoSacubitril/Valsartan | 140 | $140,183 |
| XareltoRivaroxaban | 94 | $63,949 |
| Repatha SureclickEvolocumab | 52 | $40,906 |
| JardianceEmpagliflozin | 19 | $19,655 |
| Praluent PenAlirocumab | 12 | $8,859 |
| Metoprolol Succinate | 518 | $4,957 |
| Atorvastatin Calcium | 514 | $3,996 |
| Ranolazine ErRanolazine | 21 | $3,424 |
| Potassium Chloride | 105 | $2,430 |
| ClopidogrelClopidogrel Bisulfate | 278 | $1,978 |
| Torsemide | 111 | $1,798 |
| Carvedilol | 211 | $1,565 |
| Digoxin | 56 | $1,530 |
| Amiodarone Hcl | 176 | $1,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24 | $449,407425 claims |
| NovartisEntresto | $472 | $140,183140 claims |
| Johnson & JohnsonXarelto | $38 | $63,94994 claims |
| Boehringer IngelheimJardiance | $91 | $19,65519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
- Filip OleszakOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.